Patents by Inventor Matthew Germinaro

Matthew Germinaro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
    Publication number: 20240141032
    Abstract: A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial subcutaneous dose and subsequent subcutaneous doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.
    Type: Application
    Filed: October 27, 2022
    Publication date: May 2, 2024
    Inventors: Matthew Germinaro, Mobolaji Olurinde, Aparna Sahoo, Jacqueline Yee, Omoniyi Adedokun
  • METHOD OF TREATING INFLAMMATORY BOWEL DISEASE WITH A COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF ALPHA
    Publication number: 20240010718
    Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-? inhibitor, such as an anti-TNF-? antibody (e.g., golimumab).
    Type: Application
    Filed: June 1, 2023
    Publication date: January 11, 2024
    Inventors: Matthew Germinaro, Christopher O'Brien, Jacqueline Perrigoue
  • Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
    Patent number: 11780911
    Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-? inhibitor, such as an anti-TNF-? antibody (e.g., golimumab).
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: October 10, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Matthew Germinaro, Christopher O'Brien, Jacqueline Perrigoue
  • Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
    Publication number: 20230159633
    Abstract: A method of treating ulcerative colitis in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial dose and subsequent doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.
    Type: Application
    Filed: November 22, 2022
    Publication date: May 25, 2023
    Inventors: Matthew Germinaro, Kuan-hsiang Gary Huang, Hongyan Zhang
  • Method of Treating Inflammatory Bowel Disease with a Combination Therapy of Antibodies to IL-23 and TNF Alpha
    Publication number: 20220372129
    Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF? inhibitor, such as an anti-TNF? antibody (e.g., golimumab).
    Type: Application
    Filed: May 19, 2022
    Publication date: November 24, 2022
    Inventors: Matthew Germinaro, Christopher O'Brien, Jacqueline Perrigoue, Marion Vetter